STERIS (STE) Stock Forecast & Price Target

$261.32 +7.88 (+3.11%)

As of 10:25 AM Eastern

Compare

STERIS - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for STE.

Consensus Price Target

$283.50
8.49% Upside

According to the 6 analysts' twelve-month price targets for STERIS, the average price target is $283.50. The highest price target for STE is $305.00, while the lowest price target for STE is $270.00. The average price target represents a forecasted upside of 8.49% from the current price of $261.32.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STE Analyst Ratings Over Time

Type	Current Forecast 11/13/25 to 11/13/26	1 Month Ago 10/14/25 to 10/14/26	3 Months Ago 8/15/25 to 8/15/26	1 Year Ago 11/13/24 to 11/13/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$283.50	$271.33	$271.33	$273.50
Forecasted Upside	8.49% Upside	24.86% Upside	16.51% Upside	4.99% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

STERIS Stock vs. The Competition

Type	STERIS	Healthcare Companies	Broader Market
Consensus Rating Score	2.75	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	9.01% Upside	113.87% Upside	13.84% Upside
News Sentiment Rating	Positive News See Recent STE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
11/9/2026	Weiss Ratings 2 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
11/6/2026	KeyCorp 3 of 5 stars	Brett Fishbin 2 of 5 stars	Boost Target	Overweight	$269.00 ➝ $284.00	+13.45%
8/7/2026	UBS Group 4 of 5 stars	Patrick Wood Not Rated	Lower Target	Buy	$275.00 ➝ $270.00	+13.59%
8/7/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Jason Bednar Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight	$270.00 ➝ $275.00	+16.19%
8/8/2025	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Patrick Wood Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$276.00 ➝ $295.00	+22.18%
5/29/2025	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	David Windley Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Hold	$263.00	+7.33%
5/16/2025	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
5/16/2025	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	David Turkaly Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Market Outperform	$265.00 ➝ $280.00	+11.84%
5/15/2025	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Steven Etoch Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight	$250.00 ➝ $250.00	+1.92%
4/7/2025	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Matson Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold
Get the Latest News and Ratings for STE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:18 AM ET.

Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 9, 2026. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

Here are some ways that investors could benefit from investing in STERIS plc:

STERIS plc recently reported second-quarter fiscal 2027 earnings of $2.94 per share, significantly beating the consensus estimate of $2.68, driven by strong revenue growth of 9% to $1.6 billion and margin expansion aided by tariff refunds.
The company raised its full-year fiscal 2027 earnings per share outlook to a range of $11.35 to $11.55, up from the previous forecast of $11.10 to $11.30, reflecting improved profitability and lower interest costs.
STERIS plc currently trades at $257.42, which is below the consensus analyst price target of $276.33, suggesting potential upside as the stock maintains a Moderate Buy rating from sell-side analysts.
Adjusted gross margin expanded by 100 basis points to 45.3% in the latest quarter, with approximately $20 million in tariff refunds contributing to this improvement, indicating strong operational efficiency and pricing power.
Institutional interest is growing, with several hedge funds such as CenterBook Partners LP and Rakuten Investment Management Inc. increasing their holdings or establishing new positions in the third quarter, signaling confidence in the company's future performance.

STERIS
Bear Case

Investors should be bearish about investing in STERIS plc for these reasons:

Free cash flow for the first six months of fiscal 2027 declined to $492.5 million from $527.7 million a year earlier, primarily due to lower working-capital contributions and cash used to build inventory for the second half of the year.
STERIS plc is planning the acquisition of Xodus Medical, which requires new credit agreements and may introduce integration risks and additional debt, potentially impacting future financial flexibility.
Insider selling has been notable, with multiple executives and directors, including CEO Daniel A. Carestio and Director Mohsen Sohi, selling significant portions of their shares in recent months, which may signal reduced internal confidence.
Short interest has increased slightly, with shares shorted rising to 2,397,345 in the latest reporting period, indicating that some investors are betting against the stock's future performance.
The stock's price-to-earnings ratio of 22.76 is relatively high compared to some peers, and some analysts suggest the stock could be overvalued despite the raised earnings outlook, posing a risk if growth slows.

STE Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $283.50, with a high forecast of $305.00 and a low forecast of $270.00.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STE shares.

According to analysts, STERIS's stock has a predicted upside of 8.49% based on their 12-month stock forecasts.

Over the previous 90 days, STERIS's stock had 3 upgrades by analysts.

STERIS has been rated by research analysts at Jefferies Financial Group, KeyCorp, Morgan Stanley, and Weiss Ratings in the past 90 days.

Analysts like STERIS more than other "healthcare" companies. The consensus rating for STERIS is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how STE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With STERIS Recommendations

MarketBeat monitors more than a dozen sources for STERIS analyst ratings, with the most recent rating issued on 11/13/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Stock Forecast & Price Target

STERIS - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

STE Analyst Ratings Over Time

STE Analyst Recommendations By Month

STE Price Targets by Month

STERIS Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy STERIS Stock? STE Pros and Cons Explained

STERIS
Bull Case

STERIS
Bear Case

STE Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With STERIS Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Stock Forecast & Price Target

STERIS - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

STE Analyst Ratings Over Time

STE Analyst Recommendations By Month

STE Price Targets by Month

STERIS Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy STERIS Stock? STE Pros and Cons Explained

STERIS Bull Case

STERIS Bear Case

STE Forecast - Frequently Asked Questions

What is STERIS's forecast for 2027?

Should I buy or sell STERIS stock right now?

Does STERIS's stock price have much upside?

Has STERIS been upgraded by Wall Street analysts recently?

What analysts cover STERIS?

Do Wall Street analysts like STERIS more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With STERIS Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

STERIS
Bull Case

STERIS
Bear Case